Trial · NCT01753076
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival | Placebo | 15.0 | Standard Error 13.58 | Scores on a scale | |
| Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival | Ozanezumab 15 mg/kg | -14.9 | Standard Error 13.54 | Scores on a scale | |
| Change From Baseline in the ALSFRS-R Total Score at Week 48 | Placebo | -9.1 | Standard Error 0.64 | Scores on a scale | |
| Change From Baseline in the ALSFRS-R Total Score at Week 48 | Ozanezumab 15 mg/kg | -10.4 | Standard Error 0.64 | Scores on a scale | |
| Rate of Decline Over Week 48 in the ALSFRS-R Total Score | Placebo | -0.84 | Standard Error 0.063 | change in scores on a scale per month | |
| Rate of Decline Over Week 48 in the ALSFRS-R Total Score | Ozanezumab 15 mg/kg | -0.96 | Standard Error 0.062 | change in scores on a scale per month | |
| Change From Baseline in Slow Vital Capacity (SVC) at Week 48 | Placebo | -0.899 | Standard Error 0.0804 | Liters (L) | |
| Change From Baseline in Slow Vital Capacity (SVC) at Week 48 | Ozanezumab 15 mg/kg | -1.026 | Standard Error 0.0804 | Liters (L) | |
| Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48 | Placebo | -34.7 | Standard Error 3.77 | Percent change | |
| Change From Baseline in Muscle Strength as Measured by Hand Held Dynamometry (HHD) Score at Week 48 | Ozanezumab 15 mg/kg | -42.9 | Standard Error 3.75 | Percent change | |
| Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48 | Placebo | 23 | Participants | ||
| Number of Clinical Global Impression-improvement Scale (CGI-I) Responders at Week 48 | Ozanezumab 15 mg/kg | 18 | Participants | ||
| Overall Survival at Week 48 and Week 60 | Placebo | Week 48 | 95.5 | 95% Confidence Interval 92.0 to 99.0 | Percentage of participants |
| Overall Survival at Week 48 and Week 60 | Ozanezumab 15 mg/kg | Week 48 | 94.3 | 95% Confidence Interval 90.4 to 98.1 | Percentage of participants |
| Overall Survival at Week 48 and Week 60 | Placebo | Week 60 | 87.4 | 95% Confidence Interval 81.5 to 93.3 | Percentage of participants |
| Overall Survival at Week 48 and Week 60 | Ozanezumab 15 mg/kg | Week 60 | 85.4 | 95% Confidence Interval 79.4 to 91.3 | Percentage of participants |
| Progression-free Survival at Week 48 | Placebo | 30.8 | 95% Confidence Interval 23.0 to 38.6 | Percentage of participants surviving | |
| Progression-free Survival at Week 48 | Ozanezumab 15 mg/kg | 28.5 | 95% Confidence Interval 21.1 to 35.9 | Percentage of participants surviving | |
| Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48 | Placebo | -0.234 | Standard Error 0.0207 | Scores on a scale | |
| Change From Baseline in the EuroQol 5 Dimensions-5 Level Short Form (EQ-5D-5L) Utility Score at Week 48 | Ozanezumab 15 mg/kg | -0.238 | Standard Error 0.0207 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01753076/results